Erlotinib in the treatment of advanced squamous cell NSCLCFiala, O.; Pesek, M.; Finek, J.; Krejci, J.; Havel, L.; Hrnciarik, M.; Salajka, F.; Bortlicek, Z.; Benesova, L.; Minarik, M. · Neoplasma · 2014

Skin Rash as Useful Marker of Erlotinib Efficacy in NSCLC and Its Impact on Clinical PracticeFIALA, O.; PESEK, M.; FINEK, J.; KREJCI, J.; RICAR, J.; BORTLICEK, Z.; BENESOVA, L.; MINARIK, M. · Neoplasma · 2012

Second line treatment in advanced non-small cell lung cancer (NSCLC): Comparison of efficacy of Erlotinib and chemotherapyFIALA, O.; PESEK, M.; FINEK, J.; KREJCI, J.; BORTLICEK, Z.; BENESOVA, L.; MINARIK, M. · Neoplasma · 2012

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLCFiala, O.; Pesek, M.; Finek, J.; Benesova, L.; Bortlicek, Z.; Minarik, M. · Neoplasma · 2013

73P GENE MUTATIONS IN SQUAMOUS-CELL NSCLC: INSIGNIFICANCE OF EGFR, KRAS AND PIK3CA MUTATIONS IN PREDICTION OF EGFR-TKI TREATMENT EFFICACYFiala, O.; Pesek, M.; Finek, J.; Benesova, L.; Bortlicek, Z.; Minarik, M. · Lung Cancer · 2013

Hypertrophic cardiomyopathyMaron, Barry J; Maron, Martin S · The Lancet · 2013

Noonan syndromeRoberts, Amy E; Allanson, Judith E; Tartaglia, Marco; Gelb, Bruce D · The Lancet · 2013

Pemphigoid diseasesSchmidt, Enno; Zillikens, Detlef · The Lancet · 2013

Fukushima: no ChernobylBurki, Talha Khan · The Lancet Oncology · 2013

SCIENCE AND RELIGION.The Lancet · 1925

GRAMICIDIN S REVIEW OF RECENT WORKGause, G.F. · The Lancet · 1946

GOITRE AND IODINE DEFICIENCY IN EUROPESUBCOMMITTEEFORTHESTUDYOFENDE, · The Lancet · 1985

Muscular dystrophiesMercuri, Eugenio; Muntoni, Francesco · The Lancet · 2013